Sabres GM's Admission About Key Management Members' Workplace Locations Doesn't Reflect Well On Organization
Jarmo Kekalainen (Kyle Robertson, USA TODAY Images)
Buffalo Sabres GM Kevyn Adams met with media Tuesday, weighing in on a number of topics including the future of RFA winger J.J. Peterka. But while Adams was evasive on Peterka's future, one admission Adams made was equally troubling -- namely, the place where senior adviser to the GM Jarmo Kekalainen was operating from.
Advertisement
According to Adams, Kekalainen is working remotely from Columbus, where he spent 11 years as GM of the Blue Jackets. That means both Kekalainen and associate GM Jason Karrmanos, who lives in Pittsburgh, both will be working outside of Buffalo. And while we're not suggesting that Kekalainen and Karmanos can't contribute meaningfully from their homes, the truth is the optics of the situation do not behoove the Sabres.
Ideally, a team should absolutely want their management team to all be in the same location. You get a better feel for the team when you're in the city the team plays in. You can hear from the fan base directly, and you can talk to the players face-to-face. Karmanos and Kekalainen won't be able to do that, at least, not in a meaningful manner.
It's also a negative comment on Buffalo itself when you can't convince crucial management members to live in Western New York. If it's about money, then Sabres ownership should be stepping up and spending whatever it takes to convince Kekalainen and Karmanos to relocate to Buffalo. If it's about family considerations, make it worth their while monetarily to uproot their lives to live in Buffalo. And if they can't do that, maybe Kekalainen and Karmanos aren't the right guys for the job.
Again, in the modern age where people work remotely in all kinds of professions, it wouldn't be totally outlandish if one assistant GM or management member was working out of a different city. But two management members is another thing entirely. It would be one thing if Adams could point to things Kekalainen and Karmanos have already accomplished working remotely, but starting things off on this foot just doesn't feel right.
Sabres Potential Trade Partner: Dallas Stars
Sabres Potential Trade Partner: Dallas Stars The NHL's off-season is upon us, and there are going to be many moves made on the trade and free-agent fronts. And in this THN.com Sabres site exclusive series, we're breaking down potential trade partners for Buffalo.
Advertisement
Ideally, you want all your management members in the same office. It's easier to find consensus, and it's easier to read each other's body language and mannerisms when you're in the same room. But this current Sabres management setup doesn't allow for that. Adams, Karmanos and Kekalainen will all be in Zoom meetings or other types of conference calls, and there's something that feels second-rate about that.
We'll gladly eat our words if Buffalo makes appropriate changes and earns a playoff spot for the first time in a decade-and-a-half. But if that doesn't happen, everything about the way Adams is choosing to do business will rightfully be called into question. And having two-thirds of the Sabres' upper-echelon management team will be fairly criticized at this time next year.
You can live with one key management member not living in the same city their team plays in. But having two key management members living elsewhere only underscores the (unfair) painting of Buffalo as a town no one wants to be in.
Sabres Potential Trade Partner: Pittsburgh Penguins
Sabres Potential Trade Partner: Pittsburgh Penguins The NHL's 2025 off-season is here, and teams are going to be jockeying for trades and free agents in the coming days and weeks. And in this ongoing
Advertisement
THN.com Buffalo Sabres site series, we've been examining potential trade partners for the Sabres.
In a better world, the Sabres would be pushing potential management hires out of the way as they all jockey to live and work in Buffalo. But that's not happening right now, and that's going to be a point of contention if things don't go well for the Sabres in 2025-26.
In a perfect world, Adams, Karmanos and Kekalainen all would be living and working together. Instead, they're in three different cities. Fans and media are going to be hyper-aware of that fact as every move Adams makes comes under increasingly-intense scrutiny.
And if the Sabres once again come up short when it comes to qualifying for the post-season, Adams' decision to allow key team members to work outside of Buffalo will be pinpointed as a particularly erroneous move.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Breaking: Celtics Trade Kristaps Porzingis In 3-Team Deal
Breaking: Celtics Trade Kristaps Porzingis In 3-Team Deal originally appeared on The Spun. After weeks of rumors, the Boston Celtics have parted ways with Kristaps Porzingis. Earlier this week, the Celtics dealt Jrue Holiday to the Portland Trail Blazers for Anfernee Simons and a pair of second-round picks. That move clears $4.7 million in salary for Boston. In order to continue clearing money, it's imperative the franchise parts ways with expensive assets like Porzingis. Advertisement "Porzingis I definitely think that they are in discussions with. And again, you can't just trade him off, they would be trading him for a player, probably who makes less money," ESPN insider Brian Windhorst said on Tuesday. "They would need someone to sort of be a big man, starting-level big man for Porzingis if they made this deal. But look for a Porzingis thing." It didn't take long for Windhorst's comments about Porzingis to age well. According to Shams Charania of ESPN, the Celtics are trading away Porzingis in a three-team deal that involves the Atlanta Hawks and Brooklyn Nets. Here's a breakdown of the trade: Advertisement Celtics receive: Georges Niang and a second-round pick Hawks receive: Kristaps Porzingis and a second-round pick Nets receive: Terance Mann and Atlanta's No. 22 pick Boston, MA - June 9: Boston Celtics center Kristaps Porzingis, middle, stands during the national anthem with forward Sam Hauser, left, and guard Jrue Holiday before Game 2 of the 2024 NBA Finals. (Photo by Danielle Parhizkaran/The Boston Globe via Getty Images)With Porzingis out of the picture, the focus now shifts over to Derrick White and Jaylen Brown. Windhorst claims the Celtics don't want to trade either player, but they'll most likely listen to offers. "As for the other two star players, I don't think Derrick White and Jalen Brown are players that they want to trade. Having said that, if somebody calls with a gigantic offer, I think that they would have to discuss it," Windhorst said. Charania added that teams have shown interest in Brown, which makes sense considering he's a proven All-Star. We'll see if the Celtics continue trading away key players from last year's championship roster. Advertisement Breaking: Celtics Trade Kristaps Porzingis In 3-Team Deal first appeared on The Spun on Jun 24, 2025 This story was originally reported by The Spun on Jun 24, 2025, where it first appeared.
Yahoo
30 minutes ago
- Yahoo
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Ongoing phase 2 study evaluating riliprubart for the potential prevention and treatment of active antibody-mediated rejection in kidney transplant recipients Riliprubart was also designated orphan drug for the investigational use in chronic inflammatory demyelinating polyneuropathy in the US and EU Paris, June 25, 2025. The US Food and Drug Administration (FDA) has granted orphan drug designation to riliprubart for the investigational treatment of antibody-mediated rejection (AMR) in solid organ transplantation. This designation reflects Sanofi's commitment to addressing a critical unmet need in transplant medicine, where AMR remains a significant challenge with no FDA-approved treatments available. The FDA grants orphan drug designation to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the US. Global Therapeutic Area Development Head, Immunology and Inflammation, Sanofi"Orphan drug designation for riliprubart marks an important milestone in our mission to address critical challenges in transplant medicine leveraging our expertise in immunology. Antibody mediated rejection represents a serious threat to transplanted organs and patient survival. Through riliprubart's innovative mechanism of action, we hope to bring forward a treatment option that could significantly improve outcomes for kidney transplant recipients." Riliprubart is currently being explored in multiple clinical studies across different indications in transplant and neurology. A phase 2 clinical study is currently ongoing, exploring its potential in kidney transplant recipients (NCT05156710). The study includes two patient cohorts: those at risk of developing rejection and those with active forms of antibody-mediated rejection. In addition, Sanofi is conducting two phase 3 studies exploring riliprubart in chronic inflammatory demyelinating polyneuropathy (CIPD), a rare neurological disorder, specifically in patients refractory to standard of care (MOBILIZE, clinical study identifier: NCT06290128), and in IVIg-treated patients (VITALIZE, clinical study identifier: NCT06290141). The broad clinical development program for riliprubart emphasizes Sanofi's commitment to exploring riliprubart's potential across multiple immune-mediated conditions with high unmet medical needs. About Riliprubart SAR445088 (riliprubart) is a potential first-in-class, IgG4 humanized monoclonal antibody that selectively inhibits activated C1s in the classical complement pathway of the innate immune system. Riliprubart is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority. For more information on riliprubart clinical studies, please visit About AMRAntibody-mediated rejection is a serious complication that may arise after solid organ transplantation, occurring when the recipient's immune system produces antibodies that attack the transplanted organ. Sensitized recipients, who have pre-existing antibodies that target foreign antigens including those found on transplanted organs, face a high risk of developing antibody-mediated rejection. Subsequent immune response can lead to inflammation, organ damage, and organ failure if left untreated. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Evan Berland | +1 215 432 0234 | Léo Le Bourhis | +33 6 75 06 43 81 | Victor Rouault | +33 6 70 93 71 40 | Timothy Gilbert | +1 516 521 2929 | Léa Ubaldi | +33 6 30 19 66 46 | Investor RelationsThomas Kudsk Larsen | +44 7545 513 693 | Alizé Kaisserian | +33 6 47 04 12 11 | Felix Lauscher | +1 908 612 7239 | Keita Browne | +1 781 249 1766 | Nathalie Pham | +33 7 85 93 30 17 | Tarik Elgoutni | +1 617 710 3587 | Thibaud Châtelet | +33 6 80 80 89 90 | Yun Li | +33 6 84 00 90 72 | Sanofi forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group. Attachment Press Release
Yahoo
31 minutes ago
- Yahoo
Truist Lowers GitLab (GTLB) PT to $75, Maintains Buy Rating
GitLab Inc. (NASDAQ:) is one of the best technology stocks according to Wall Street analysts. Earlier on June 12, Truist adjusted the price target for GitLab to $75 from $80, while maintaining a Buy rating on the shares. This revision comes after GitLab's Q1 2025 results, which, although exceeding guidance, did not meet investor expectations for a larger beat. In Q1, the company reported a total revenue of $169.2 million, which marked a 33% increase year-over-year. GitLab also generated positive cash flow for the first time in a first quarter. The subscription revenue from self-managed and SaaS grew to $151.179 million from $111.191 million year-over-year, and license revenue from self-managed and other increased to $18.008 million from $15.687 million. A team of software engineers working together in an open office, developing innovative solutions. The company's customer base also expanded, with customers contributing over $5,000 of ARR, reaching 8,976, which showed a 21% increase year-over-year. Customers with over $100,000 of ARR grew by 35% year-over-year, totaling 1,025. In this quarter, GitLab also received the 2024 Google Cloud Technology Partner of the Year Award in the Application Development – DevOps category. GitLab Inc. (NASDAQ:GTLB) develops software for the software development lifecycle in the US, Europe, and the Asia Pacific. While we acknowledge the potential of GTLB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data